Skip to content

NVS Price, Chart & Factor Exposure

Free Data & Analytics Access
NVS · E.NVS.NEO · Canada
Use symbol E.NVS.NEO in our API & Excel add-in to retrieve this data ↓
—
(—)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum —
Trend —
Bubble Risk LOW
Realised Volatility (20D) —

NVS Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
NVS
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
NVS
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
NVS
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for NVS, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on NVS

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

About NVS (Canada)

NVS is a listed security in Canada. This page shows the latest price and daily change, a price chart, its factor exposures and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Novartis AG ADR

Frequently asked questions

What is NVS?
NVS is a listed security in Canada. On MacroFinance its page shows the latest price and daily change, a price chart, its factor exposures and free historical data.
What factors affect NVS?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to NVS, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Where can I download free NVS historical data?
In the Free historical data section of this page: the last 10 years of NVS daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free NVS historical data (last 10 years)

Browse or instantly download the last 10 years of NVS daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NVS.NEO&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-05-2828.07
2026-05-2728.24
2026-05-2629.17
2026-05-2529.17
2026-05-2228.3
2026-05-2128.3
2026-05-2028.28
2026-05-1928.35
2026-05-1527
2026-05-1427
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.